INTERNATIONAL ISOTOPES Business Summary

Radnostix, Inc. (formerly International Isotopes Inc.) operates a diversified nuclear medicine and industrial radiation business model, generating revenue through the manufacture, distribution, and contract manufacturing of radioisotopes and specialized medical devices. The company’s primary business segments include Theranostics Products, which focuses on generic Sodium Iodide I-131 and radiochemical APIs; Cobalt Products, providing Cobalt-60 sealed sources and recycling services; and Nuclear Medicine Standards, which produces calibration and reference standards under the RadQual brand. Additionally, the company is expanding into Medical Devices with its RadVent line (Swirler® and Tru-Fit™) and maintains a Fluorine Products segment for high-purity gas production. Radnostix competes directly with global entities such as Eckert & Ziegler, QSA Global, and Nordion, positioning itself as a specialized domestic provider of high-purity isotopes and essential diagnostic standards within the North American market. Leadership is currently spearheaded by President and CEO Shahe Bagerdjian, who assumed the role in 2023 following a decade-long tenure at Global Medical Solutions (GMS) and recently signed a contract extension through 2030 to lead the company’s rebranding and strategic expansion. The company was founded in 1995 and was long-guided by Steve T. Laflin, who served as CEO for over 20 years and remains an influential member of the Board of Directors. Governance is further strengthened by Chairman Christopher G. Grosso, a significant investor with extensive capital markets expertise, and Dr. Duke W. Fu, a Board Certified Nuclear Pharmacist and former CEO of Green Therapeutics who joined the board in late 2025. This executive team is focused on transitioning the company from a legacy industrial isotope manufacturer into a premier partner in the global theranostics and radiopharmaceutical sectors.